Leads & Contacts 0709
This article was originally published in RPM Report
Key figures involved in issues covered in September RPM Features
You may also be interested in...
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
The hot new buzzword with policymakers is comparative clinical effectiveness, and everyone has an idea on how to make it work. But major questions remain: what might a national effort look like? And will payors use it to restrict access to new drugs?
Pfizer's Lipitor is taking a beating as payors push use of generic statins wherever possible. But Lipitor and many other blockbuster brands may get some unexpected relief when Medicaid changes its payment rules for generics next year.